Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2204-2211

  Fahmi, Odette A ^a   Raucy, Judy L ^b   Ponce, Elsa ^b   Hassanali, Saleema ^b   Lasker, Jerome M ^b  

^a PFIZER INC   (United States)

^b Puracyp Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; ATORVASTATIN; AVASIMIBE; BOSENTAN; CARBAMAZEPINE; CYTOCHROME P450 3A; EFAVIRENZ; ETHINYLESTRADIOL; HYPERFORIN; LUCIFERASE; MIDAZOLAM; MODAFINIL; NAFCILLIN; NEVIRAPINE; NIFEDIPINE; OXCARBAZEPINE; PHENOBARBITAL; PIOGLITAZONE; PLECONARIL; PREGNANE X RECEPTOR; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; SULFINPYRAZONE; TERBINAFINE; TOPIRAMATE; TRIAZOLAM; TROGLITAZONE; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CAR GENE; CELL STRAIN DPX2; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYP3A GENE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; EXPRESSION VECTOR; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MDR1 GENE; MRP GENE; OAT GENE; OCT1 GENE; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PXR GENE; REPORTER GENE; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; UPREGULATION;

CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; HEP G2 CELLS; HUMANS; MIDAZOLAM; RECEPTORS, STEROID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867674181     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047456     Document Type: Article

References (32)

1. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, and Pavek P (2007) Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35:1032-1041. (Pubitemid 46956421)
2. Fahmi OA, Boldt S, Kish M, Obach RS, and Tremaine LM (2008a) Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971-1974.
3. Fahmi OA, Kish M, Boldt S, and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
4. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008b) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
5. Fahmi OA and Ripp SL (2010) Evaluation of models for predicting drug-drug interactions due to induction. Expert Opin Drug Metab Toxicol 6:1399-1416.
6. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, and Wang H (2006) Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 317:1200-1209. (Pubitemid 43764125)
7. Gibson GG, Plant NJ, Swales KE, Ayrton A, and El-Sankary W (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165-206. (Pubitemid 34267348)
8. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
9. Hosomi H, Fukami T, Iwamura A, Nakajima M, and Yokoi T (2011) Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos 39:1388-1395.
10. Karam WG, Goldstein JA, Lasker JM, and Ghanayem BI (1996) Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 24:1081-1087. (Pubitemid 26346220)
11. Ko JW, Sukhova N, Thacker D, Chen P, and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862. (Pubitemid 27318604)
12. Konno Y, Negishi M, and Kodama S (2008) The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab Pharmacokinet 23:8-13.
13. Krueger SK, Williams DE, Yueh MF, Martin SR, Hines RN, Raucy JL, Dolphin CT, Shephard EA, and Phillips IR (2002) Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab Rev 34:523-532. (Pubitemid 35006063)
14. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431. (Pubitemid 36378519)
15. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646. (Pubitemid 36329382)
16. Manceau S, Giraud C, Declèves X, Batteux F, Chouzenoux S, Tang R, Dauchy S, Scherrmann JM, Weill B, Morini JP, et al. (2010) Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes. Int J Pharm 395:98-103.
17. Meisenheimer PL, Uyeda HT, Ma D, Sobol M, McDougall MG, Corona C, Simpson D, Klaubert DH, and Cali JJ (2011) Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition. Drug Metab Dispos 39:2403-2410.
18. Mills JB, Rose KA, Sadagopan N, Sahi J, and de Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303-309. (Pubitemid 38393143)
19. Neunzig I, Drǎ;gan CA, Widjaja M, Schwaninger AE, Peters FT, Maurer HH, and Bureik M (2011) Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. Biochim Biophys Acta 1814:161-167.
20. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, and Meyer UA (2006) Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80:440-456.
21. Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S, and Goldstein JA (2010) Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 38:591-599.
22. Raucy J, Warfe L, Yueh MF, and Allen SW (2002) A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 303:412-423.
23. Raucy JL and Lasker JM (2010) Current in vitro high throughput screening approaches to assess nuclear receptor activation. Curr Drug Metab 11:806-814.
24. Richert L, Tuschl G, Abadie C, Blanchard N, Pekthong D, Mantion G, Weber JC, and Mueller SO (2009) Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol 235:86-96.
25. Robertson P Jr, Hellriegel ET, Arora S, and Nelson M (2002) Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 71:46-56. (Pubitemid 34124038)
26. Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, and Xia M (2011) Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151-159.
27. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
28. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, and Breimer DD (1992) Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 42:319-324.
29. Trubetskoy O, Marks B, Zielinski T, Yueh MF, and Raucy J (2005) A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J 7:E6-E13. (Pubitemid 41554304)
30. Wang Z, Hall SD, Maya JF, Li L, Asghar A, and Gorski JC (2003) Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85. (Pubitemid 36110842)
31. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891. (Pubitemid 34815417)
32. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, and Asahi S (2001) Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro 15:245-256. (Pubitemid 32476834)